Clinical stage Bioscience Company focusing on treatment of mental illness ATAI Life Sciences says that it’s anticipating to raise $100 million from its upcoming initial public offering. The company made its IPO regulatory filing with the U.S Securities and Exchange Commission on April 21.
According to the regulatory filing, ATAI raised an average of $362.3 million from a private placement by investors.
ATAI is planning to get listed on NASDAQ under the ticker symbol ‘ATAI’ the company failed to disclose its IPO date claiming the date is yet to be agreed upon but it will keep on making updates on the matter as they occur.
The company develops depression drugs and it’s currently working on developing psychedelics drugs to treat anxiety, cognitive impairment linked to schizophrenia and post-traumatic stress disorder (PTSD).
ATAI has offices in New York, Berlin and San Diego it has already signed partnership deals with around 14 companies on drug development and other related technologies.
